Atazanavir vs Darunavir — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Protease Inhibitor

Atazanavir

Brand: Atazanavir Sulfate

First FDA approval: 2003-06-24

Protease Inhibitor

Darunavir

Brand: PREZISTA

First FDA approval: 2008-03-08

Lowest NADACAcquisition cost floor across all NDCs

$1.09Per unit

$1.13Per unit

Average NADACAcross all dosage forms and strengths

$1.89Up to $2.70

$5.94Up to $70.19

Generic manufacturersActive ANDA holders — FDA Orange Book

414 total ANDAs filed

1023 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$6.8MFull year

$81.7MFull year

Part D claims (CY24)Total fills, all strengths

16K3K beneficiaries

92K16K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$428Per claim, all NDCs

$886Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes4 manufacturers

Yes10 manufacturers